Oversight Subcommittee Investigation Prompts FDA to Issue Warning Letter to JUUL
Washington, D.C. (Sept. 9, 2019)—Today, Rep. Raja Krishnamoorthi, the Chairman of the Subcommittee on Economic and Consumer Policy, issued the following statement after the Food and Drug Administration (FDA) issued a warning letter to JUUL Labs, Inc. three days after Chairman Krishnamoorthi urged the FDA to evaluate admissions and statements made by JUUL representatives under oath during a hearing before the Subcommittee:
“Today’s action by the Food and Drug Administration to begin holding JUUL Labs accountable for its illegal marketing and outreach practices would not have happened without the efforts of the Subcommittee’s ongoing investigation into JUUL Labs and the broader youth vaping epidemic. Last week, I wrote to the FDA urging such action while providing it with findings from our investigation into JUUL’s marketing of their products to children and without scientific support for its health claims. I’m glad to see the agency has finally acted while directly citing testimony from our Subcommittee’s, but this is only a first step. While I hope the FDA continues its efforts to hold JUUL accountable and combat the youth vaping epidemic, our Subcommittee absolutely will.”
The FDA sent a letter to JUUL Labs today declaring that it violated the law and “expressing concern, and requesting more information, about several issues raised in a recent Congressional hearing regarding JUUL’s outreach and marketing practices, including those targeted at students, tribes, health insurers and employers.”
In July, Rep. Krishnamoorthi released a memo based on approximately 55,000 non-public documents JUUL produced to the Subcommittee and the Massachusetts Attorney General in response to the Subcommittee’s investigation launched in June.